Articles
The development and utilization of novel therapies, including
small-molecule agents, have undoubtedly altered
the treatment landscape for many indolent
non-Hodgkin B-cell malignancies in the frontline and relapsed/
refractory settings. The availability of such agents as
Bruton tyrosine kinase, BCL2, and phosphoinositide 3-kinase
(PI3K) inhibitors addresses an unmet need among oncologists
and advanced practice providers (APPs) who are seeking additional
therapeutic options for their patients, particularly
those with relapsed/refractory disease. Read More ›
On May 19, 2020, the FDA approved a new indication for olaparib (Lynparza; AstraZeneca), a PARP inhibitor, for the treatment of men with metastatic castration-resistant prostate cancer and deleterious or suspected deleterious germline or somatic HRR mutation, as determined by an FDA-approved test, whose disease progressed after enzalutamide (Xtandi) or abiraterone acetate (Zytiga) therapy. Olaparib is the first FDA-approved PARP inhibitor for prostate cancer. Read More ›
On May 18, 2020, the FDA approved a new indication for atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, for the first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) whose tumor has high PD-L1 expression (PD-L1 stained ≥50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥10% of the tumor area), and no EGFR or ALK genomic aberrations, as determined by an FDA-approved test. Read More ›
The federal government is an active participant in shaping and delivering healthcare policy. The panelists in this session addressed the government’s response to COVID-19 and weighed in on some of the issues that their agencies frequently encountered as medical practices grapple with the new normal. Read More ›
Nurses are on the front lines like no other healthcare personnel. In this panel, distinguished nursing professionals discussed topics and issues that have arisen during the pandemic. Led by healthcare educator Lillie D. Shockney, the comprehensive panel covered some of the myriad issues nurse navigators confront now, including rising cancer rates in an aging population, and a decline in numbers of oncology nurses and oncologists. Read More ›
The May issue of The Oncology Pharmacist (TOP) is filled with important news and insights for today’s oncology pharmacist. We begin our coverage with highlights of a recent webinar from the Association for Value-Based Cancer Care (AVBCC), in which healthcare experts addressed the impact of the COVID-19 pandemic on oncology delivery systems and the management of patients with cancer. Read More ›
On April 3, 2020, the Association for Value-Based Cancer Care (AVBCC) held a webcast with healthcare experts representing major industry stakeholders to address the impact of the COVID-19 pandemic on oncology delivery systems and the management of patients with cancer. Read More ›
By Wayne Kuznar
San Francisco, CA—De-escalating chemotherapy based on a negative positron-emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium. Read More ›
By Wayne Kuznar
San Francisco, CA—Platinum-based therapy represents a new standard of care in patients with pancreatic cancer and germline BRCA or PALB2 mutation, based on data reported at the 2020 Gastrointestinal Cancers Symposium. Read More ›
Although medical cannabis has been used successfully as a palliative therapy in patients with cancer, it is still stigmatized because of its illicit scheduling. Read More ›